panzyga® is a treatment for people with certain immune system disorders.

This website provides:

  • information on immune system disorders and immunoglobulin therapy for the general public
  • resources for patients already prescribed panzyga®
  • product information for healthcare professionals

Patient Information Leaflet (PIL)

Download

Summary of Product Characteristics (SPC)

Download

Assessment Report by Paul Ehrlich Institut (PEI)

Download

Safety Reporting Information for Patients and the Public: This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

Safety Reporting Information for Healthcare Professionals: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Octapharma by telephoning 0845 1300 522.


Octapharma is a global company that specialises in the development and production of human proteins.

Details of clinical trials sponsored by Octapharma are provided at clinicaltrials.gov and clinicaltrialsregister.eu


Copyright © 2017 | Octapharma | Legal Statement | Privacy Statement
Octapharma Ltd, The Zenith Building, 26 Spring Gardens, Manchester M2 1AB 
2017.007.C  Date of preparation: March 2017